Prognostic value of tumor suppressors in osteosarcoma before and after neoadjuvant chemotherapy

BMC Cancer

Table 1 Clinicopathologic characteristics of high-grade osteosarcoma patients and IHC of six biomarkers

Variables	n_BX	%_BX	n_RX	%_RX
All high grade osteosarcoma	48	100	47	100
Neoadjuvant chemotherapy	48	100	47	100
Sex
Female	19	40	17	36
Male	29	60	30	64
Patient age
<10 years	10	21	9	19
10–24 years	31	65	31	66
>24 years	7	15	7	15
Histological subtype
Osteoblastic	34	71	33	70
Chondroblastic	4	8	7	15
Fibroblastic	5	10	4	9
Telangiectatic	5	10	3	6
Location
Tibia / Fibula / Calcaneus	19	40	15	32
Femur	18	38	20	43
Humerus / Ulna	6	13	5	11
Axial	5	10	7	15
Pathologic Response
Responder	26	54	24	49
Non-Responder	22	46	23	51
Metastasis
Yes	21	44	18	38
No	27	56	29	62
P16 total (n_matchedBX-RX = 27)	44	100	39	100
P16_positive	25	57	17	44
P16_negative	19	43	22	56
P53 total (n_matchedBX-RX = 31)	47	100	44	100
P53_positive	9	19	12	27
P53_negative	38	81	32	73
PTEN total (n_matchedBX-RX = 10)	40	100	22	100
PTEN_positive	25	63	7	32
PTEN_negative	15	37	15	68
Maspin total (n_matchedBX-RX = 21)	39	100	33	100
Maspin_positive	26	67	10	30
Maspin_negative	13	33	23	70
Ki67 total (n_matchedBX-RX = 15)	43	100	25	100
Ki67_positive	24	56	8	32
Ki67_negative	19	44	17	68
BMI1 total (n_matchedBX-RX = 16)	42	100	28	100
BMI1_positive	11	26	2	7
BMI1_negative	31	74	26	93

ISSN: 1471-2407